Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RECENTIN in previously untreated metastatic colorectal cancer
NCT00399035Phase 3Completed
- Sponsor
- AstraZeneca
- Start
- Nov 2006
- Primary completion
- Mar 2010
- Modality
- Antibody Fragments, Polymer-based Nanoparticles
- Countries
- 15
01
Overview
Phase 3, randomised, double-blind trial of cediranib in metastatic colorectal cancer (mCRC), sponsored by AstraZeneca. Started Nov 2006; status: completed.
02
Drugs
cediranib
03
Conditions
metastatic colorectal cancer (mCRC)
Beyond the preview
Go deeper on NCT00399035.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00399035.